FIDSON Healthcare Plc has entered into a partnership with US firms, Immune Therapeutics, GB Pharma and American Hospitals & Resort, AHAR, for the marketing and distribution of a new product, LodonalTM, a patent-protected product for the management of patients with immune-compromising diseases.
The partnership will leverage Fidson’s strong and experienced marketing base, robust distribution channels and efficient customer and technical support services to promote LodonalTM in Nigeria.
The distribution will become effective, upon completion of the ongoing NAFDAC approved 90‐day bridging trial evaluating the efficacy and safety of the product.
Managing Director, Fidson Healthcare Plc, Dr. Fidelis Ayebae, said “Fidson is truly excited about this collaboration with Immune Therapeutics and GB Pharma/AHAR. We know that success in this industry will be dependent on having the right partnership and we would not have asked for better partners at this stage of our growth. The international experience of Immune Therapeutics and GB Pharma/AHAR in different markets and their strong commitment to research will be of immense benefit to Fidson. Likewise, Fidson’s towering presence in the Nigeria Pharma space will open a great door for the group to access one of the biggest and most rewarding markets in Africa.”
This partnership is another strategic approach by the management of Fidson Healthcare Plc, to strengthen the company’s growth. It also comes on the heels of the recent visit by President Muhammadu Buhari to the United States. The significance is monumental as a concrete symbol of US-Nigerian commerce in a non-oil/gas related sector and showcases a future for the local manufacturing of quality pharmaceuticals on the African continent.
President and CEO of GB Pharma, Dr. Gloria Herndon, said “this is the crescendo of a great partnership between GB Pharma, American Hospitals and Resorts, Immune Therapeutics, each with its distinct role. Fidson Healthcare markets and distributes throughout the extensive Nigerian network.
“We feel that Nigeria and the US bilateral relationship will benefit from this amazing initiative that will enhance the health and wellbeing of people all over the world. This is the spirit of collaboration that Presidents Obama and Buhari were talking about during the state visit.”
Fidson Healthcare Plc, recently recognised by Frost and Sullivan as the recipient of its ‘2014 Growth Excellence Leadership Award in the Nigerian Pharmaceutical Industry’, recorded sales of N9.7 billion in FY2014.
The award was in recognition of the company’s consistent performance in the pharmaceutical sector which has seen its revenue rise at a 15 percent CAGR over the last five years.
The company has also won other corporate awards including the Financial Standard ‘Pharmaceutical Sector Leader’ Award in 2008 and the ‘Nigerian Pharmaceutical Company of the Year’ at the Nigerian Healthcare Excellence Awards, NHEA, in 2014. Fidson’s definitive growth and consistent performance in the stock market also earned its CEO the 2014 BusinessDay Top 25 CEOs Award, which the company has won consecutively for two years.
To offer options in manufacturing and grow its product portfolio, Fidson will commission a N7.5 billion manufacturing plant this year. The new facility will double its production capacity and will also for the first time, add intravenous fluids to Fidson’s product portfolio. The facility is built to conform to the World Health Organisation’s (Geneva) current Good Manufacturing Practice (WHO-GMP) standards.
AHAR CEO, Dr. Richard Afonja, stated that “we are well positioned to effect this novel approach to treating HIV/AIDS and other immune compromised diseases in the whole of Africa, starting with Nigeria. Bringing Fidson on board will enhance the facilitation of getting this much needed treatment for these conditions.”
To achieve its strategic objective of consistently improving products and consolidate market position, Fidson has continued to invest in research and development across various disease areas.
This has recorded a number of firsts, key among which was becoming the first company in Sub-Saharan Africa to manufacture antiretroviral drugs in 2005.
The company has over 200 products across several therapeutic classes, which cut across anti-infectives, gastrointestinal, antiretroviral, anti-malarial, cardiovascular, analgesic, haematinics and supplements.

Ad:See How you can turn $500 into $10,000 Click HERE For Details.